A new vaccine platform for fighting emerging viruses
Official title: A Self-Adjuvanting Virus Like Particle Vaccine Platform for Emerging Viruses
Funded at Oregon Health & Science University · NIH-11092746 · Data updated 2026-11-12
This study is testing a new type of vaccine that uses special particles to help your body fight off new viruses better, so you can have a stronger and longer-lasting immune response.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | June 8, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $782,723 |
| NIH project number | 5R01AI177293-03 |
| Project ID | NIH-11092746 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of exposure to emerging viral infections, such as healthcare workers or those living in endemic areas.
✕Less likely to help
Patients who are not at risk of emerging viral infections or those with contraindications to vaccination may not benefit from this research.
What this research studies
This research focuses on developing a novel vaccine platform that utilizes virus-like particles to enhance the immune response against emerging viruses. By leveraging the protein Stimulator of Interferon Genes (STING), the project aims to improve vaccine efficacy through a self-adjuvanting mechanism. The approach involves creating cell lines that produce immunogenic particles capable of stimulating the immune system more effectively than traditional vaccines. Patients may benefit from a more robust and long-lasting immune response to viral infections.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that provide better protection against emerging viral infections.
How similar studies have gone: Other research has shown promise in using STING activation to enhance vaccine responses, indicating that this approach could be a significant advancement in vaccine development.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Defilippis, Victor Robert — Oregon Health & Science University
- Study coordinator: Defilippis, Victor Robert
Related research
Other NIH-funded projects on the same topics.
-
Understanding how a protein affects nerve cell movement in Alzheimer's disease
This study is looking at how a protein called APP affects the growth and movement of nerve cells, which is important for understanding Alzheimer's disease, and it aims to find out how problems with this protein might lead to nerve cell damage.
-
Understanding how the bone marrow environment drives AML resistance
A large NIH-funded project at Oregon Health & Science University is studying how the body’s own cell surroundings help acute myeloid leukemia become resistant to treatment, with potential paths to better therapies for patients.
-
Improving Safety at Work with a Low-Resource mHealth Program in Malaysia (and beyond)
A low-cost mobile health program to improve safety culture in Malaysian workplaces, with plans to adapt the approach for U.S. workers in high-risk industries.
-
Oregon Healthy Workplace Initiative for Better Health
A multi-site effort aims to improve the health and safety of workers by coordinating research, tools, and interventions across workplaces.
-
Understanding how AML cells become resistant to therapy over time
This project looks at why acute myeloid leukemia stops responding to treatment and how to design better drug combinations to prevent relapse.
-
Mechanisms and Countermeasures for Ultra-Potent Synthetic Opioid Overdose
A small, focused NIH grant aims to understand why ultra-potent synthetic opioids cause severe overdose and to explore potential countermeasures to keep people safe.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.